Agenus PE Ratio 2010-2022 | AGEN
Current and historical p/e ratio for Agenus (AGEN) from 2010 to 2022. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Agenus PE ratio as of February 03, 2023 is 0.00.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Agenus PE Ratio Historical Data |
| Date |
Stock Price |
TTM Net EPS |
PE Ratio |
| 2023-02-03 |
2.57 |
|
0.00 |
| 2022-09-30 |
2.05 |
$-0.81 |
0.00 |
| 2022-06-30 |
1.94 |
$0.10 |
19.40 |
| 2022-03-31 |
2.46 |
$-0.10 |
0.00 |
| 2021-12-31 |
3.22 |
$-0.18 |
0.00 |
| 2021-09-30 |
5.25 |
$-0.12 |
0.00 |
| 2021-06-30 |
5.49 |
$-1.12 |
0.00 |
| 2021-03-31 |
2.72 |
$-1.03 |
0.00 |
| 2020-12-31 |
3.18 |
$-1.07 |
0.00 |
| 2020-09-30 |
4.00 |
$-1.09 |
0.00 |
| 2020-06-30 |
3.93 |
$-1.14 |
0.00 |
| 2020-03-31 |
2.45 |
$-1.24 |
0.00 |
| 2019-12-31 |
4.07 |
$-0.81 |
0.00 |
| 2019-09-30 |
2.58 |
$-0.99 |
0.00 |
| 2019-06-30 |
3.00 |
$-0.95 |
0.00 |
| 2019-03-31 |
2.97 |
$-0.81 |
0.00 |
| 2018-12-31 |
2.38 |
$-1.46 |
0.00 |
| 2018-09-30 |
2.14 |
$-1.41 |
0.00 |
| 2018-06-30 |
2.27 |
$-1.49 |
0.00 |
| 2018-03-31 |
4.71 |
$-1.57 |
0.00 |
| 2017-12-31 |
3.26 |
$-1.22 |
0.00 |
| 2017-09-30 |
4.41 |
$-1.17 |
0.00 |
| 2017-06-30 |
3.91 |
$-1.27 |
0.00 |
| 2017-03-31 |
3.77 |
$-1.28 |
0.00 |
| 2016-12-31 |
4.12 |
$-1.47 |
0.00 |
| 2016-09-30 |
7.18 |
$-1.35 |
0.00 |
| 2016-06-30 |
4.05 |
$-1.04 |
0.00 |
| 2016-03-31 |
4.16 |
$-1.24 |
0.00 |
| 2015-12-31 |
4.54 |
$-1.15 |
0.00 |
| 2015-09-30 |
4.60 |
$-1.38 |
0.00 |
| 2015-06-30 |
8.63 |
$-1.35 |
0.00 |
| 2015-03-31 |
5.13 |
$-0.94 |
0.00 |
| 2014-12-31 |
3.97 |
$-0.67 |
0.00 |
| 2014-09-30 |
3.11 |
$-0.42 |
0.00 |
| 2014-06-30 |
3.22 |
$-0.53 |
0.00 |
| 2014-03-31 |
3.17 |
$-0.81 |
0.00 |
| 2013-12-31 |
2.64 |
$-1.15 |
0.00 |
| 2013-09-30 |
2.77 |
$-1.22 |
0.00 |
| 2013-06-30 |
3.79 |
$-1.22 |
0.00 |
| 2013-03-31 |
3.89 |
$-1.13 |
0.00 |
| 2012-12-31 |
4.10 |
$-0.49 |
0.00 |
| 2012-09-30 |
4.61 |
$-0.55 |
0.00 |
| 2012-06-30 |
5.24 |
$-0.59 |
0.00 |
| 2012-03-31 |
6.60 |
$-0.58 |
0.00 |
| 2011-12-31 |
2.00 |
$-1.17 |
0.00 |
| 2011-09-30 |
2.82 |
$-1.06 |
0.00 |
| 2011-06-30 |
4.68 |
$-1.14 |
0.00 |
| 2011-03-31 |
5.46 |
$-1.14 |
0.00 |
| 2010-12-31 |
6.06 |
$-1.44 |
0.00 |
| 2010-09-30 |
5.94 |
$-1.14 |
0.00 |
| 2010-06-30 |
4.87 |
$-1.56 |
0.00 |
| 2010-03-31 |
4.36 |
$-2.28 |
0.00 |
| 2009-12-31 |
3.84 |
$-2.52 |
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.783B |
$0.296B |
|
Agenus Inc., formerly known as Antigenics Inc., is engaged in the discovery, development and commercialization of immunotherapeutics for the treatment of life threatening and chronic medical conditions. Immunotherapeutics are drugs that work by modulating the immune system to fight diseases. The Company's product line includes Oncophage vaccine, a patient-specific therapeutic cancer vaccine. The Company is also developing Prophage, patient-specific therapeutic cancer vaccine; QS-21, vaccine adjuvant; and HerpV, a polyvalent off-the-shelf therapeutic heat shock protein-based vaccine for treatment of genital herpes which are all in the clinical testing stages. Agenus Inc. is headquartered in Lexington, Massachusetts.
|
